Mycamine (micafungin sodium) for Injection
Approved: March 16, 2005 Company: Fujisawa Healthcare, Inc.
Treatment for:
Candida Infections Mycamine is a member of a new class of antifungal agents, the echinocandins, which inhibit cell-wall synthesis. Mycamine is used for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal candidiasis.
Back to
Latest FDA Approvals 
FDA Approves Mycamine 
Linear Mode
